Uroflowmetry and Ultrasound Measurement of Residual Urine in Early Parkinson`s Disease

Urovesical dysautonomic symptoms are present in 27-97% of the patients with Parkinson's disease (PD) dependingon patients' selection criteria and methods used. The micturitional disturbances are typical of patients with more severe PD. The authors studied the urovesical function in 23 PD patients aged 41-60 years and without subjective micturitional complaints by uroflowmetry and ultrasound measurement of residual urine. Urovesical disturbances were established in 30,4% of the patients. The average results for Max Flow Rate (MFR) were 21,85 ±5,49 ml/sec and for residual urine 27,83 ±25,58 ml. The most influencing factor was the severity of the disease measured by the UPDRS. Our results were important additions to the existing information on the urovesical function in PD. Dysautonomic micturitional disturbances were found even in patients without subjective complaints in the early stages of the disease. Their degree correlated most closely to the severity of PD. The necessity of specialized examiantions of dysautonomic urovesical symptoms imposes the presence of a tailor-made patient approach for their early detection and adequate treatment

Analysis of Rail Yard and Terminal Performances

One of the latest trends in the transport field is the increasing interest for the rejuvenation of the railway. It is considered to be a logical consequence of the gradual switch towards a more sustainable future in transports. Terminals and stations are considered to be the junction points between the various lines that constitute the railway network and can simply be described as points of arrival, departure and interchange of passengers or commodities. The most commonly used indicators that measure the level of their performance are time and cost. This study aims at exploring possible improvements that could be implemented to the infrastructure and the operation of terminals and stations in order to increase the efficiency level. Firstly, drawing upon grounded theory, a description is conducted, followed by a comparative analysis of the different types of existing terminals and stations. Secondly, the suggested improvements are presented in accordance with their time frame completion. The main contribution of the study is to illustrate the high significance of terminals, stations and yards, given the fact that they are considered to be crucial parts of the railway network. In addition to this, great emphasis is given to the need of improving and developing the existing terminal infrastructure and operations

DarkCideS 1.0, a global database for bats in karsts and caves

Tanalgo, Krizler C., Tabora, John Aries G., de Oliveira, Hernani Fernandes Magalhães, Haelewaters, Danny, Beranek, Chad T., Otálora-Ardila, Aída, Bernard, Enrico, Gonçalves, Fernando, Eriksson, Alan, Donnelly, Melissa, González, Joel Monzón, Ramos, Humberto Fernández, Rivas, Alberto Clark, Webala, Paul W., Deleva, Stanimira, Dalhoumi, Ridha, Maula, Jaycelle, Lizarro, Dennis, Aguirre, Luis F., Bouillard, Nils, Quibod, Ma. Niña Regina M., Barros, Jennifer, Turcios-Casco, Manfredo Alejandro, Martínez, Marcio, Ordoñez-Mazier, Diego Iván, Orellana, José Alejandro Soler, Ordoñez-Trejo, Eduardo J., Ordoñez, Danny, Chornelia, Ada, Lu, Jian Mei, Xing, Chen, Baniya, Sanjeev, Muylaert, Renata L., Dias-Silva, Leonardo Henrique, Ruadreo, Nittaya, Hughes, Alice Catherine (2022): DarkCideS 1.0, a global database for bats in karsts and caves. Scientific Data 9 (1): 155, DOI: 10.1038/s41597-022-01234-4, URL: http://dx.doi.org/10.1038/s41597-022-01234-

A concept for integrated care pathways for atopic dermatitis-A GA2 LEN ADCARE initiative

INTRODUCTION: The integrated care pathways for atopic dermatitis (AD-ICPs) aim to bridge the gap between existing AD treatment evidence-based guidelines and expert opinion based on daily practice by offering a structured multidisciplinary plan for patient management of AD. ICPs have the potential to enhance guideline recommendations by combining interventions and aspects from different guidelines, integrating quality assurance, and describing co-ordination of care. Most importantly, patients can enter the ICPs at any level depending on AD severity, resources available in their country, and economic factors such as differences in insurance reimbursement systems. METHODS: The GA2 LEN ADCARE network and partners as well as all stakeholders, abbreviated as the AD-ICPs working group, were involved in the discussion and preparation of the AD ICPs during a series of subgroup workshops and meetings in years 2020 and 2021, after which the document was circulated within all GAL2 EN ADCARE centres. RESULTS: The AD-ICPs outline the diagnostic procedures, possible co-morbidities, different available treatment options including differential approaches for the pediatric population, and the role of the pharmacists and other stakeholders, as well as remaining unmet needs in the management of AD. CONCLUSION: The AD-ICPs provide a multidisciplinary plan for improved diagnosis, treatment, and patient feedback in AD management, as well as addressing critical unmet needs, including improved access to care, training specialists, implementation of educational programs, assessment on the impact of climate change, and fostering a personalised treatment approach. By focusing on these key areas, the initiative aims to pave the way for a brighter future in the management of AD

DarkCideS 1.0, a global database for bats in karsts and caves.

Understanding biodiversity patterns as well as drivers of population declines, and range losses provides crucial baselines for monitoring and conservation. However, the information needed to evaluate such trends remains unstandardised and sparsely available for many taxonomic groups and habitats, including the cave-dwelling bats and cave ecosystems. We developed the DarkCideS 1.0 ( https://darkcides.org/ ), a global database of bat caves and species synthesised from publicly available information and datasets. The DarkCideS 1.0 is by far the largest database for cave-dwelling bats, which contains information for geographical location, ecological status, species traits, and parasites and hyperparasites for 679 bat species are known to occur in caves or use caves in part of their life histories. The database currently contains 6746 georeferenced occurrences for 402 cave-dwelling bat species from 2002 cave sites in 46 countries and 12 terrestrial biomes. The database has been developed to be collaborative and open-access, allowing continuous data-sharing among the community of bat researchers and conservation biologists to advance bat research and comparative monitoring and prioritisation for conservation

Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.

BACKGROUND: Ischemic stroke is the leading cause of mortality worldwide and a major contributor to neurological disability and dementia. Terutroban is a specific TP receptor antagonist with antithrombotic, antivasoconstrictive, and antiatherosclerotic properties, which may be of interest for the secondary prevention of ischemic stroke. This article describes the rationale and design of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic Attack (PERFORM) Study, which aims to demonstrate the superiority of the efficacy of terutroban versus aspirin in secondary prevention of cerebrovascular and cardiovascular events. METHODS AND RESULTS: The PERFORM Study is a multicenter, randomized, double-blind, parallel-group study being carried out in 802 centers in 46 countries. The study population includes patients aged > or =55 years, having suffered an ischemic stroke (< or =3 months) or a transient ischemic attack (< or =8 days). Participants are randomly allocated to terutroban (30 mg/day) or aspirin (100 mg/day). The primary efficacy endpoint is a composite of ischemic stroke (fatal or nonfatal), myocardial infarction (fatal or nonfatal), or other vascular death (excluding hemorrhagic death of any origin). Safety is being evaluated by assessing hemorrhagic events. Follow-up is expected to last for 2-4 years. Assuming a relative risk reduction of 13%, the expected number of primary events is 2,340. To obtain statistical power of 90%, this requires inclusion of at least 18,000 patients in this event-driven trial. The first patient was randomized in February 2006. CONCLUSIONS: The PERFORM Study will explore the benefits and safety of terutroban in secondary cardiovascular prevention after a cerebral ischemic event.Journal ArticleMulticenter StudyRandomized Controlled TrialResearch Support, Non-U.S. Gov'tinfo:eu-repo/semantics/publishe